5,003 results on '"MARTINELLI, GIOVANNI"'
Search Results
2. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
3. Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series
4. MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
5. A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications
6. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
7. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
8. Nilotinib : a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
9. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
10. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
11. Geochemical characteristics of natural springs within the Lenglongling fault zone related to the Menyuan Ms 6.9 earthquake on January 8, 2022, NW China
12. Earthquake geochemical scientific expedition and research
13. Personalizing precision medicine: Patients with AML perceptions about treatment decisions
14. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia
15. Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
16. Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
17. Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
18. Notes for a History of Gas Geochemistry
19. Fall predictors in hospitalized patients living with cancer: a case–control study
20. Geochemical features and seismic imaging of the tectonic zone between the Tibetan Plateau and Ordos Block, central northern China
21. The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
22. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
23. Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial.
24. 68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.
25. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.
26. Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches
27. Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease
28. Heterogeneous self-tracked health and fitness data integration and sharing according to a linked open data approach
29. Effects of yoga practice on physiological distress, fatigue and QOL in patients affected by breast cancer undergoing adjuvant radiotherapy
30. Geochemical and geophysical effects of tectonic activity in faulted areas of the North China Craton
31. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
32. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
33. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
34. Patients with multiple myeloma referred for palliative care consultation: from retrospective analysis to future directions to improve clinical outcomes
35. CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
36. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
37. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
38. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
39. CometAnalyser: A user-friendly, open-source deep-learning microscopy tool for quantitative comet assay analysis
40. Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
41. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
42. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
43. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
44. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
45. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
46. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel
47. Two-dimensional segmentation fusion tool: an extensible, free-to-use, user-friendly tool for combining different bidimensional segmentations
48. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS
49. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
50. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.